Publications by authors named "Ulrich Mey"

Claim this Profile
U
Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.
Martina Bertschinger, Holger W Auner, Veronika Ballova, Carmen De Ramon Ortiz, Christoph Driessen, Ulrich Mey

Swiss Med Wkly· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020.
Linmiao Jiang, Marco Ladetto, Olivier Hermine, Johanna C Kluin-Nelemans, Jan Walewski, Ulrich Mey

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial.
Justin Ferdinandus, Helen Kaul, Alexander Fosså, Andreas Hüttmann, Felix Keil, Ulrich Mey

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Impact of the AML60+ Score for Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A Retrospective Multicentric Analysis.
Verena Petermichl, Stefan Fuchs, Matthias Weber, Katrin Gobat, Charlotte Micheloud, Ulrich J M Mey

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network.
Max J Rieger, Andreas J Flammer, Sabine Gerull, Thomas Pabst, Holger W Auner, Ulrich Mey

Swiss Med Wkly· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib lead-in followed by venetoclax plus ibrutinib for relapsed/refractory chronic lymphocytic leukemia: the SAKK 34/17 trial.
Adalgisa Condoluci, Ilaria Romano, Daniel Dietrich, Katia Pini, Georg Stüssi, Ulrich Mey

Blood· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Six-month rituximab-lenalidomide regimen in advanced untreated follicular lymphoma: SAKK 35/10 trial 10-year update.
Eva Kimby, Sämi Schär, Maria Cristina Pirosa, Anna Vanazzi, Ulrich M Mey

Blood Adv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies.
Jeroen S Goede, Christa K Baumann, Richard Cathomas, Nina Khanna, Jean-Francois Lambert, Ulrich J M Mey

Swiss Med Wkly· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Martin Dreyling, Jeanette Doorduijn, Eva Giné, Mats Jerkeman, Jan Walewski, Ulrich Mey

Lancet· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Urban Novak, Martin Fehr, Sämi Schär, Martin Dreyling, Christian Schmidt, Ulrich Mey

EClinicalMedicine· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Decision-Making among Experts in Advanced Hodgkin Lymphoma.
Felicitas Hitz, Noémie Lang, Ulrich Mey, Walter Mingrone, Alden Moccia

Oncology· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial.
Thilo Zander, Thomas Pabst, Sämi Schär, Stefan Aebi, Ulrich Mey

Leukemia· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcome of older myeloma patients in relationship to comorbidities and availability of second-generation novel agents in a real-life setting.
Murielle Lalive d'Epinay, Sabine Güsewell, Nicole Graf, Ulrich J M Mey, Christoph Driessen

Hematol Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma.
Anastasios Stathis, Ulrich Mey, Sämi Schär, Felicitas Hitz, Christiane Pott

Blood Adv· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.
Meletios A Dimopoulos, Philippe Moreau, Evangelos Terpos, María-Victoria Mateos, Sonja Zweegman, Ulrich Mey

Hemasphere· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic.
Martin Dreyling, Igor Aurer, Massimo Federico, Mats Jerkeman, Marie Jose Kersten, Ulrich Mey

Hemasphere· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Rudolf Benz, Kornelius Arn, Martin Andres, Thomas Pabst, Michael Baumann, Ulrich Mey

Blood Adv· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08.
Martin Fehr, Hanne Hawle, Stefanie Hayoz, Peter Thuss-Patience, Sabina Schacher, Ulrich Mey

BMC Cancer· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy.
Emanuele Zucca, Stephanie Rondeau, Anna Vanazzi, Bjørn Østenstad, Ulrich J M Mey

Blood· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.
Michael Mark, Dirk Klingbiel, Ulrich Mey, Ralph Winterhalder, Christian Rothermundt

Clin Genitourin Cancer· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland.
Panagiotis Samaras, Mario Bargetzi, Daniel C Betticher, Christoph Driessen, Michel A Duchosal, Ulrich Mey

Swiss Med Wkly· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.
Anton W Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Ulrich J M Mey

Blood· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and treatment of follicular lymphoma: an update.
Mario Bargetzi, Reto Baumann, Sergio Cogliatti, Pierre-Yves Dietrich, Michel Duchosal, Ulrich Mey

Swiss Med Wkly· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Ulrich Mey

Blood· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib-induced rapid response in chemotherapy-refractory Richter's syndrome.
Angela Fischer, Sara Bastian, Sergio Cogliatti, Ulrich Mey, Jenny Saub

Hematol Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis